SHANGHAI, July 27, 2021 /PRNewswire/-- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering patient management, online healthcare
information, professional training and educational services, today
announced that for the first half of 2021, around 100,000 users had
completed the learnings through the Breast Cancer Tiered Diagnosis
and Treatment Improvement Platform ("Platform") built and operated
by the Company.
There are approximately 2.5 million breast cancer patients in
China, with more than 400,000 new
cases each year. The 5-year survival rate for patients with
early-stage breast cancer is up to 90% compared to less than 40%
for patients with advanced breast cancer. The Healthy China 2030
Guideline outlines the goal of increasing the overall 5-year cancer
survival rate by 15% by 2030. The overall treatment level of breast
cancer in developed regions of China is now close to the level of the
developed countries. However, many breast cancer patients are
diagnosed at the advanced stage, and the level of treatment varies
from region to region. As a result, in order to improve the
survival rate of breast cancer patients, the capacities of breast
cancer diagnosis and treatment in grassroots and underdeveloped
areas are essentially important.
Tiered diagnosis and treatment is an important system
implemented by the National Health Commission, which aims to
rationalize the allocation of medical resources and promote the
equal availability of basic medical and health services, covering
over 90% of the regions nationwide. National Health Commission had
announced the Technical Plan for Breast Cancer Tiered Diagnosis and
Treatment, enabling many breast cancer patients to receive
standardized treatment at the grassroots level. There are currently
approximately 4 million grassroots health care providers in
China. To achieve the goal of
expanded tiered diagnosis and treatment, it is necessary to provide
training on standardized treatment for primary health care
providers.
The Platform is a standardized diagnosis and treatment education
platform. Through the construction of the clinical competence
model, multi-dimensional lecture format, and real-time guidance by
authoritative experts, the Platform provides comprehensive training
for doctors and county medical institutions nationwide regarding
the breast cancer diagnosis and treatment in prefecture-level as
well as application of advanced breast cancer treatment technology
in primary medical and health institutions. Renowned experts in the
field of breast cancer in China,
such as Prof. Shao Zhimin, Prof. Jiang Zefei, Prof. Xu Binghe and
Prof. Jin Feng have joined the
platform as lecturers or instructing experts. The Platform is built
and operated by the Company and jointly supported by China Primary
Health Care Foundation, Cancer Hospital of Chinese Academy of
Medical Sciences, Beijing Cancer Hospital, Fudan University
Shanghai Cancer Center, Tianjin Medical University Cancer Institute
and Hospital, AstraZeneca, etc.
With the continuous launch of innovative drugs, the market size
of China breast cancer drugs
continues to grow. By the end of 2020, the market size of
China breast cancer drugs was
50.1 billion Yuan with an 11.33%
year-over-year increase, and it is expected to increase to
73.9 billion Yuan in 2024. Moreover,
with the implementation of tiered diagnosis and treatment,
companies and organizations in the pharmaceutical field are
devoting more attention and resources to the primary care market,
and there is a huge market opportunity for the education and
training of millions of primary care health service personnel.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online
provider of healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. The Company also provides patient
management services through its subsidiaries. More information
about the Company can be found at its investor relations website at
http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions; the
growth of the professional training and educational services market
in China and the other
international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-builds-a-platform-for-breast-cancer-tiered-diagnosis-and-treatment-improvement-to-promote-the-equalization-of-breast-cancer-diagnosis-and-treatment-level-301341214.html
SOURCE Zhongchao Inc.
